Leo Pharma begins phase IIb study of oral atopic dermatitis drug
Pharmaceutical firm Leo Pharma has recruited the first patient for a clinical IIb trial to test the oral candidate in adults with moderate-to-severe atopic dermatitis.
by ulrich quistgaard, translated by daniel pedersen
Clinical testing in a phase IIb study with a tablet treatment for moderate-to-severe atopic dermatitis in adult patients is now starting, says Leo Pharma in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma starts phase II trial of Korean tablet
For subscribers
FDA fast tracks former Leo Pharma eczema candidate
For subscribers
